IRIS Institutional Research Information System - OPENBS Open Archive UniBS

CAVAZZANA, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.796
EU - Europa 7.548
AS - Asia 5.373
SA - Sud America 1.030
AF - Africa 134
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 10
Totale 24.901
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.611
IT - Italia 4.054
SG - Singapore 1.942
CN - Cina 1.813
UA - Ucraina 929
BR - Brasile 862
DE - Germania 638
HK - Hong Kong 533
FR - Francia 400
VN - Vietnam 375
FI - Finlandia 327
GB - Regno Unito 314
IE - Irlanda 229
RU - Federazione Russa 224
TR - Turchia 188
IN - India 150
CA - Canada 89
BD - Bangladesh 87
NL - Olanda 71
AR - Argentina 68
SE - Svezia 59
MX - Messico 51
IQ - Iraq 48
ES - Italia 46
ZA - Sudafrica 46
AT - Austria 42
JP - Giappone 35
PL - Polonia 35
PK - Pakistan 28
BE - Belgio 27
EE - Estonia 24
ID - Indonesia 23
EC - Ecuador 22
RO - Romania 21
LT - Lituania 20
MA - Marocco 20
VE - Venezuela 19
AE - Emirati Arabi Uniti 16
SA - Arabia Saudita 16
UZ - Uzbekistan 16
CO - Colombia 15
NG - Nigeria 15
JO - Giordania 14
KE - Kenya 14
IL - Israele 13
CH - Svizzera 12
EG - Egitto 12
JM - Giamaica 12
KZ - Kazakistan 11
PY - Paraguay 11
CZ - Repubblica Ceca 10
AU - Australia 9
EU - Europa 9
PE - Perù 9
AZ - Azerbaigian 8
CL - Cile 8
UY - Uruguay 8
DZ - Algeria 7
MK - Macedonia 7
PH - Filippine 7
KG - Kirghizistan 6
LU - Lussemburgo 6
PA - Panama 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
DK - Danimarca 5
HN - Honduras 5
IR - Iran 5
LV - Lettonia 5
NO - Norvegia 5
PT - Portogallo 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
GR - Grecia 4
HU - Ungheria 4
NP - Nepal 4
AO - Angola 3
CR - Costa Rica 3
CY - Cipro 3
DO - Repubblica Dominicana 3
LI - Liechtenstein 3
MU - Mauritius 3
MY - Malesia 3
OM - Oman 3
PS - Palestinian Territory 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TN - Tunisia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
ET - Etiopia 2
KR - Corea 2
LB - Libano 2
LK - Sri Lanka 2
LY - Libia 2
MT - Malta 2
Totale 24.870
Salva come PNG Salva come JPEG
Città #
Fairfield 1.061
Singapore 1.001
Ashburn 889
Woodbridge 800
Jacksonville 680
Houston 584
Hong Kong 532
San Jose 496
Beijing 438
Seattle 423
Cambridge 418
Wilmington 415
The Dalles 395
Ann Arbor 377
Milan 322
Princeton 310
New York 296
Chandler 280
Los Angeles 268
Nanjing 224
Rome 215
Chicago 212
Helsinki 204
Dublin 167
Lauterbourg 157
Istanbul 150
Ho Chi Minh City 135
Brescia 133
Dallas 113
Florence 107
Buffalo 99
Munich 91
Des Moines 89
Moscow 88
Nanchang 84
Salt Lake City 82
São Paulo 71
Hanoi 69
San Diego 67
Hebei 64
Redondo Beach 64
Turin 63
San Francisco 61
Shenyang 60
Trieste 59
Lancaster 57
Bologna 55
Changsha 55
Verona 55
Council Bluffs 52
London 50
Tianjin 50
Shanghai 48
Jinan 44
Genoa 39
Jiaxing 39
Orem 37
Santa Clara 36
Brooklyn 35
Dearborn 35
Tampa 35
Elk Grove Village 34
Nuremberg 34
Udine 34
Tokyo 33
Frankfurt am Main 32
Padova 32
Turku 30
Toronto 28
Brussels 27
Phoenix 27
Rio de Janeiro 27
Chennai 25
Pisa 25
Bergamo 24
Genova 24
Kunming 24
Mumbai 24
Tallinn 24
Atlanta 23
Johannesburg 23
Modena 23
Belo Horizonte 22
Naples 22
Warsaw 22
Hangzhou 21
Syracuse 21
Vienna 21
Guangzhou 20
Menlo Park 20
Amsterdam 19
Falkenstein 19
Montreal 19
Palermo 19
Baghdad 18
Ningbo 18
Reggio Nell'emilia 18
Catania 17
Torino 17
Denver 16
Totale 14.561
Salva come PNG Salva come JPEG
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.381
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.827
Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis 703
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 221
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 220
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 216
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 215
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 197
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 196
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 192
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 184
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 183
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 181
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 179
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 177
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 177
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 173
Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept 173
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 171
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 169
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 168
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 163
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 163
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 158
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 156
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 156
Autoimmune polyendocrine Syndromes 155
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 155
The clinico-serological spectrum of overlap myositis 155
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 154
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 152
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 150
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 145
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 145
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 143
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 141
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 140
Anti-Ro/SSA and La/SSB antibodies 140
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 139
Renal Involvement in Primary Antiphospholipid Syndrome: Retrospective Analysis of 160 Patients. 139
Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase 139
A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. 138
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 138
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 138
A prospective evaluation of endothelial dysfunction in Systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results. 138
A prospective evaluation of endothelial dysfunction in systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results 136
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis 136
Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? 135
Endothelium and the brain in CNS lupus. 135
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 133
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 132
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 131
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 131
Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome 130
[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects] 130
Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis 129
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 128
Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy 128
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 127
Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors 127
Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data 127
ANTI-RNA POLYMERASE III ANTIBODIES AS A RISK MARKER FOR EARLY DEVELOPMENT OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS 124
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 124
The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: A multicenter evaluation and a review of the literature 124
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 124
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 123
Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. 122
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 122
Serologic profile and mortality rates of scleroderma renal crisis in Italy 121
Complement Activation and Pregnancy Failure. 120
LUPUS ERITEMATOSO SISTEMICO AD ESORDIO TARDIVO: CARATTERISTICHE CLINICHE ED IMMUNOLOGICHE 120
Autoantibodies and Skin Involvement in Systemic Autoimmune Diseases 119
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 118
Ten Year Risk of Cardiovascular Events during anti-TNF Alpha in Rheumatoid Arthritis Patients 118
AUMENTO DELLA PROTEINA C-REATTIVA, ANTICORPI ANTI-CCP E FATTORE REUMATOIDE NELL'ARTRITE LUPICA 117
Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations 117
International cohort study of 73 anti-Ku-positive patients: Association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis 117
Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. 117
Anti-Ku antibodies in connective tissue disease: clinical and serologic evaluation of 14 patients. 116
Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. 116
CLINICAL AND IMMUNOLOGICAL ASSOCIATION WITH AUTOANTIBODIES TO CELLULAR ANTIGEN IN A COHORT OF 532 SLE PATIENTS FROM A SINGLE CENTER 116
Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients 116
Update on Antiphospholipid Syndrome: Ten Topics in 2017 116
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis 115
Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis 115
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. 115
Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients 115
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 114
Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. 114
Cardiological features in idiopathic inflammatory myopathies. 114
ANTICORPI ANTI-SU NELLA SINDROME DA ANTICORPI ANTI-FOSFOLIPIDI PRIMARIA (PAPS) 113
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 113
Anti-Ro/SSA autoantibodies over time in mothers of children with congenital complete heart block. 112
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 112
Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients 111
Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety 111
Complement cascade in systemic lupus erythematosus: Analyses of the three activation pathways 110
Rare Autoantibodies To Cellular Antigens In Systemic Lupus Erythematosous. 110
Value Of Diastolic Dysfunction In Asymptomatic Rheumatoid Arthritis Patients Without Cardiovascular Risk Factors 109
Comparison of early and late onset systemic lupus erythematosus 109
Totale 18.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021409 0 0 0 0 0 0 0 0 0 0 281 128
2021/20221.997 113 248 112 106 116 147 151 154 135 195 180 340
2022/20231.482 207 26 45 64 115 331 36 164 257 50 102 85
2023/20241.543 81 52 120 121 86 278 82 68 330 58 62 205
2024/20254.119 70 75 59 366 368 358 262 159 354 317 853 878
2025/20266.597 632 976 510 925 631 486 1.049 267 401 541 179 0
Totale 25.196